Drug Designing: Open Access
Open Access
ISSN: 2169-0138
ISSN: 2169-0138
Felix Neumann*
Structure-Based Drug Design (SBDD) has emerged as a cornerstone of modern oncology drug discovery, particularly in the targeted inhibition of oncogenic kinases. These kinases, which are mutated or dysregulated in various cancers, serve as prime therapeutic targets due to their essential roles in cell signaling, proliferation and survival. Unlike traditional high- throughput screening, which relies on testing vast compound libraries for biological activity, SBDD begins with detailed three- dimensional knowledge of the target protein's structure. This rational approach allows scientists to design small-molecule inhibitors that fit precisely into the active site or regulatory pockets of kinases, maximizing efficacy and selectivity while minimizing off-target effects.
Published Date: 2025-03-04; Received Date: 2025-02-03